InfuSystem (NYSE:INFU) Downgraded by Zacks Research to "Hold"

Key Points

• InfuSystem has been downgraded by Zacks Research from a "strong-buy" rating to a "hold," reflecting a shift in investor sentiment.
• The company's current market consensus rating is "Buy," with an average price target of $13.50 according to recent analyst evaluations.
• In insider trading news, Director Scott Shuda sold shares amounting to a 5.77% decrease in his position, valued at approximately $908,980.

InfuSystem (NYSE:INFU - Get Free Report) was downgraded by Zacks Research from a "strong-buy" rating to a "hold" rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms also recently issued reports on INFU. Roth Capital assumed coverage on shares of InfuSystem in a research note on Tuesday, July 22nd. They set a "buy" rating and a $12.00 price objective for the company. Lake Street Capital initiated coverage on shares of InfuSystem in a research note on Monday, September 22nd. They issued a "buy" rating and a $15.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, InfuSystem presently has a consensus rating of "Buy" and an average price target of $13.50.

InfuSystem Price Performance

INFU opened at $10.17 on Monday. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. InfuSystem has a 52-week low of $4.61 and a 52-week high of $11.04. The company has a 50 day moving average of $9.52 and a two-hundred day moving average of $6.97. The company has a market cap of $207.73 million, a P/E ratio of 169.53 and a beta of 1.79.

Insider Buying and Selling

In other InfuSystem news, Director Scott Shuda sold 5,752 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the transaction, the director directly owned 94,000 shares in the company, valued at $908,980. This represents a 5.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 11.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Brevan Howard Capital Management LP bought a new position in InfuSystem during the 2nd quarter valued at $228,000. Bank of America Corp DE boosted its stake in InfuSystem by 19.4% during the 2nd quarter. Bank of America Corp DE now owns 17,994 shares of the company's stock valued at $112,000 after acquiring an additional 2,924 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in InfuSystem by 82.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 130,350 shares of the company's stock valued at $813,000 after acquiring an additional 58,810 shares during the last quarter. Jane Street Group LLC boosted its stake in InfuSystem by 943.1% during the 2nd quarter. Jane Street Group LLC now owns 186,159 shares of the company's stock valued at $1,162,000 after acquiring an additional 168,312 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in InfuSystem during the 2nd quarter valued at $33,000. 71.13% of the stock is currently owned by institutional investors.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.